Bullish news on cancer research and a looming patent publish date ETA June 1st. Earnings suck but they're shedding debt notes maybe for a buyout? Heads up on breakouts (short sellers wet dream). Cups within cups within cups. Dunno, DYOR and not investment advice.
$NXGN Target 20.85 for 17.60%
Or next add level is at 15.11
I added here and updated target... target is a little higher than before. Earnings were fine...
—
On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average.
I start every position with 1% of my account and build...
Our ABML Play seems to be working out so far. Here is another Gem that could work our similar. I love cheap stocks.
NOVN is a clinical development-stage biotechnology company, which focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases.
Checking Wallstreetzen, it appears to be...
$OBLN Target 6.65 for 43.32%
Or next add level is at 2.63
This one was fun today... still quite a ways to target but heading that way...
—
On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average.
I start every position with 1% of my account and build from there as needed...
Ultimovacs’ UV1 in combination with pembrolizumab shows 60% Objective Response Rate in advanced melanoma Phase I data
• UV1/pembrolizumab results in 30% complete responses plus 30% partial responses
• Good safety and tolerability profile supports use of UV1 in combination treatments
• Data to be presented at ASCO and abstract to be discussed in webcast on May...
Bullish harmonic. Pattern in combination of low float stock such as KMPH is very bullish setup especially since the stock has been hovering around previous highest volume day of 1M shares traded. the stock has been hovering around 900k and reluctant to break 1M but the tutes are getting anxious as investor Samuel Braun decided to add to his position and steal...
Bullish MACD cross (technical buy signal) + monster news!!
Combined Apollon and Aion Formulations Kill Breast Cancer Cells Through Multiple Pathways
LONDON and TORONTO, May 18, 2021 /PRNewswire/ -- Apollon Formularies plc (AQSE: APOL) ("Apollon" or the "Company"), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, and Aion...
$SYRS Target 8.81 for 27.68%
Or next add level is at 4.99
—
On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average.
I start every position with 1% of my account and build from there as needed and as possible.
I am not your financial advisor. Watch my setups first before...
It's been a rough ride for bios lately, but a reversal could be coming very soon. As you can see in the chart, $XBI, the biotech ETF that I like, has fallen to an important VWAP and to the 50% retracement. Today we bounced off of that level, forming a sort of hammer candle on this Heikin Ashi chart. This fund is also currently at the bottom of the daily RSI, which...
S&P Biotech ETF (XBI) is a strong Buy currently at the lower end of its weekly range. Risk/Reward looks very favorable for a long position (Buy) and holding for next 2-3 months (8-12 weeks) for targets of 150-170.
Wouldn't be surprised to see this stock break all time highs in next few months and in the next 12-months $50+.
* Key notes: 2nd generation Covid Vaccine sponsored by NIAID that's being conducted through infectious diseases clinical research consortium (IDCRC). Established collaboration with Gilead Sciences to develop a vaccine-based immunotherapy as part of...
$IBIO Target 1.91 for 21.66%
Or next add level is at 1.23
Good fun!! Sold at 2.19 two days ago and back in at 1.57... let's go!!
—
On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average.
I start every position with 1% of my account and build from there as needed and as...
$SYRS Target 9.22 for 26.13%
Or next add level is at 5.40
—
On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average.
I start every position with 1% of my account and build from there as needed and as possible.
I am not your financial advisor. Watch my setups first before...
Read about company because it earns alot of money. They produce gloves. Maybe this is the moment to buy... we will see. Great Risk Reward ratio as fundamentaly this company should be priced PLN 1500
Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and single-use...
